Teva announces availability of generic Kytril

NORTH WALES, Penn. Teva Pharmaceuticals has announced the availability of granisetron hydrochloride tablets, the generic of Kytril, following the expiration of Roche’s patent on the brand on Dec. 28.

The drug is used for the prevention of nausea and vomiting associated with initial and repeated courses of chemotherapy. The generic will be available in a 1 mg strength, in blister packs of 2 x 1 and 5 x 4.

The product had annual sales of approximately $88 million for the twelve months that ended October 2007, based on IMS sales data.